Acute Hepatitis B Infection After a Switch to Long-Acting Cabotegravir and Rilpivirine | Zendy

Claire Pintado | Zendy; Constance Delaugerre | Zendy; JeanMichel Molina | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Acute Hepatitis B Infection After a Switch to Long-Acting Cabotegravir and Rilpivirine

Author(s) -

Claire Pintado,

Constance Delaugerre,

JeanMichel Molina

Publication year - 2020

Publication title -

open forum infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.546

H-Index - 35

ISSN - 2328-8957

DOI - 10.1093/ofid/ofaa367

Subject(s) - medicine , rilpivirine , hepatitis b virus , hepatitis b , lamivudine , pill , human immunodeficiency virus (hiv) , emtricitabine , virology , antiretroviral therapy , intensive care medicine , viral load , pharmacology , virus

Maintenance antiretroviral therapy with combination of two injectable long-acting drugs, cabotegravir and rilpivirine, is a new strategy addressing the challenges of daily adherence to oral pills that has shown non-inferior efficacy to standard of care therapy in patients with suppressed HIV-infection. Patients co-infected with hepatitis B virus (HBV) are not eligible for this dual therapy since it has no activity against HBV, but this strategy should also be restricted to patients with anti-HBs antibodies since people with HIV are still at risk of HBV acquisition due to high risk behavior and since HBV vaccination does not always elicit anti-HBs antibodies, as highlighted in the case report below.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research